BRAFV600-mutant ctDNA as a Prognostic Biomarker in Resected Stage III Melanoma
1. ctDNA detection was found to have a relapse HR of 2.91 in the placebo and HR 2.98 in the ...
Tag: ctDNA
Circulating Tumor DNA-Guided De-Escalation Targeted Therapy for Advanced NSCLC
1. Patients with no biochemical or radiographic evidence of progressive disease had a median treatment break of 20.3 months. 2. ...
#VisualAbstract: Multicancer early detection blood tests show promise but warrant further clinical evaluation
1. One-third of patients with a cancer signal were correctly diagnosed to have cancer. 2. Patients in the true-positive group ...
#VisualAbstract: Circulating tumor DNA levels may predict treatment response in patients with advanced melanoma
Click to read the study in The Lancet Oncology.
#VisualAbstract: Low plasma ctDNA may be predictive of better survival outcomes in patients with melanoma receiving first-line immune checkpoint inhibitors
Click to read the study in Clinical Cancer Research
